Skip to main content
Back to Articles

Does a Multi-Ingredient Creatine and MCT Supplement Prevent Muscle Loss in Sarcopenia?

By the CreatineIQ Research Desk
Last reviewed
New Research
Musculoskeletal
Aging

Sarcopenia1, the progressive loss of muscle mass and strength associated with aging, affects over 20% of older adults in Taiwan, where this trial was conducted, and contributes to frailty and functional decline. While resistance training remains the gold standard for combating sarcopenia, researchers are actively exploring nutritional interventions for those who cannot easily engage in structured exercise. A recent randomized controlled trial investigated whether a multi-ingredient supplement containing creatine, leucine, medium-chain triglycerides (MCTs), and whey protein could mitigate these age-related declines.

Key Takeaways

  • Targeted Formulation: The study tested a multi-ingredient supplement combining whey protein, branched-chain amino acids, MCTs, creatine, resveratrol, and vitamin D3 against an isocaloric placebo.
  • Statistically Significant but Clinically Trivial Muscle Gains: While the supplement group gained muscle mass compared to the placebo group, the absolute increase fell below the widely recognized threshold for a minimal clinically important difference.
  • No Between-Group Strength Difference: Handgrip strength did not differ between the groups (p = 0.32). The placebo group declined by 7.0% over the eight weeks while the supplemented group showed no significant change, but that within-group contrast does not show that the supplement prevented the decline.

The Study Design

Researchers conducted an eight-week randomized, double-blind, placebo-controlled trial at National Taiwan University Hospital in older adults who met the Asian Working Group for Sarcopenia (AWGS) 2019 diagnostic criteria. Eighty participants were randomized (40 per group) to the multi-ingredient supplement or an isocaloric placebo daily, without a structured exercise program; 73 (average age 77.3 ± 7.7 years) completed the trial and were analysed — 34 on the supplement and 39 on placebo. The trial was registered on ClinicalTrials.gov (NCT06376266) retrospectively, in April 2024, which the authors acknowledge as a limitation.

The primary outcomes measured were changes in appendicular skeletal muscle mass (ASM) assessed via dual-energy X-ray absorptiometry (DXA2) and handgrip strength. As an exploratory endpoint, the team also performed targeted plasma amino acid metabolomics to observe shifts in amino acid utilization.

The Findings

After eight weeks, the group receiving the multi-ingredient supplement showed a statistically significant increase in appendicular skeletal muscle mass (+0.42 kg, or +3.2%) compared to the placebo group, which saw no change.

Despite this gain in physical mass, handgrip strength did not significantly differ between the two groups (p=0.32) — the primary strength outcome was null. Within-group analysis offers a more encouraging reading: the placebo group declined significantly by 7.0% (p<0.001), while the supplemented group showed no significant change (p=0.537). It is worth being precise about what that means. "No significant decline" is not the same as demonstrated preservation, and a within-group contrast is weaker evidence than the between-group comparison that found nothing.

Exploratory metabolomic profiling observed shifts in plasma amino acids — reductions in taurine and 1-methylhistidine alongside an increase in kynurenine — but with no clear separation on PCA/PLS-DA, the authors treat these as hypothesis-generating rather than confirmatory of altered proteolysis. Positively, no clinically significant adverse metabolic or renal events were reported.

Analyzing the Study: Strengths & Limitations

Strengths and Reputability

The study utilized a rigorous double-blind, placebo-controlled design, and its sample size was calculated a priori (80% power to detect a ~5% between-group difference in muscle mass). It relied on objective, gold-standard measurements for body composition (DXA), and recruited an at-risk demographic defined by an established clinical standard (AWGS 2019) rather than by self-report.

Limitations

The study suffers from several crucial limitations that impact its broader applicability. First, the sample was modest and the analysis was per-protocol: of 80 people randomized, only the 73 completers were analysed, and dropout was uneven — 6 of 40 on the supplement against 1 of 40 on placebo, with gastrointestinal discomfort the most common reason (n = 3). The authors acknowledge this may introduce attrition bias. The a priori power calculation was based on muscle mass, so the trial was not specifically sized for its strength outcome. The trial was also registered retrospectively; the authors call the delay administrative and state that the outcomes were fixed before the first participant enrolled, but the registry cannot independently confirm that. Second, because the intervention was a multi-ingredient matrix, it is impossible to isolate the specific effects or contribution of the creatine versus the whey, MCTs, or leucine. Third, the cohort was recruited at a single hospital in Taiwan and screened against AWGS criteria, which are calibrated to Asian populations; the findings may not transfer cleanly to other populations or care settings. Finally, and most importantly, the clinical significance of the findings is trivial: the authors explicitly note in the abstract that the observed increase in muscle mass fell below the minimal clinically important difference (MCID3).

Conflicts of Interest

The authors declare no conflicts of interest and state that the funders had no role in the design, analysis, writing or decision to publish. According to the full text, the research was supported by En Chu Kong Hospital (NTUH.112-EKN0003), and the authors paid the article processing charge themselves. The paper describes TLN-01 as a commercially available supplement but does not name its manufacturer or say who supplied it.

Conclusion

Overall, this well-designed but strictly incremental study suggests that an MCT-leucine-creatine-based supplement was reasonably well tolerated over eight weeks — no clinically significant adverse metabolic or renal events were reported — though that reading comes with a caveat: six of 40 participants left the supplement arm against one of 40 on placebo, gastrointestinal discomfort was the most common reason, and only completers were analysed. Whether it attenuates the decline of muscle strength is uncertain, since the between-group comparison of handgrip strength was null. However, the actual muscle mass gains were modest and clinically trivial. Without the presence of an exercise stimulus, supplementation alone produced only minimal practical benefits. Future research with larger sample sizes and isolated ingredient testing is needed to determine the optimal nutritional interventions for clinical sarcopenia.

References

  1. Chan DC, Shiao MS, Huang WJ, Huang CF. Effects of a Multi-Ingredient MCT-Leucine-Creatine-Based Supplement (TLN-01) on Muscle Mass, Strength, and Plasma Amino Acid Profiles in Older Adults with Sarcopenia: A Randomized Controlled Trial. Life (Basel). 2026;16(8):1334. DOI: 10.3390/life16081334

Glossary

  1. Sarcopenia: A progressive, age-related syndrome characterized by the generalized loss of skeletal muscle mass and strength, increasing the risk of adverse outcomes like physical disability and poor quality of life. ↩

  2. DXA (Dual-energy X-ray Absorptiometry): A highly precise imaging technique used to measure bone mineral density and body composition, including fat and lean muscle mass. ↩

  3. Minimal Clinically Important Difference (MCID): The smallest change in a treatment outcome that an individual patient or clinician would identify as important, distinguishing a statistically significant finding from a practically meaningful one. ↩